HEALEY ALS Platform Trial

Weekly Q&A – Dec 15, 2022



MGH	MASSACHUSETTS
1811	GENERAL HOSPITAL

Healey Center

Sean M. Healey & AMG Center for ALS at Mass General








































The Arthur M. Blank FAMILY FOUNDATION





The goal of the HEALEY ALS Platform Trial is to screen drugs rapidly and efficiently, get solid answers, and determine next steps



Informational Webinars about Regimen E

Trehalose/SLS-005 Drug Science and **Mechanism of Action Q&A Webinar**

Hosted by Seelos Therapeutics on 10 March 2022

Recording Available!





https://bit.ly/3L4hrdB

Recording available under "science and mechanism of action series"

The ALS Association/Northeast ALS Consortium Educational Webinar

Update on Healey ALS Platform Trial Regimen E: Trehalose for ALS

UPDATE ON REGIMEN E

Recording Available!

TREHALOSE FOR ALS



Merit Cudkowicz, MD, MSc

SEAN M. HEALEY & AMG CENTER FOR ALS AT MCH



Shafeeg Ladha, MD

BARROW NEUROLOGICAL


INSTITUTE



https://bit.ly/3X2u004

Recording available under "educational webinars" on neals.org

60 Sites Currently Activated for Regimen E



(as of 12/15/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

V UPMC Lehigh Valley Health Network \mathbf{V} Indiana University Mass General Hospital \mathbf{V} Augusta University University of Kansas V University of Utah University of Marvland V Holy Cross Hospital California Pacific Medical Center \mathbf{V} Penn State Hershey Northwestern University V University of CA, Irvine Virginia Commonwealth University V Cedars Sinai Medical Center University of Nebraska V University of Pennsylvania Washington University N Nova Southeastern University Wake Forest University V Johns Hopkins University Hospital for Special Care V Columbia University Saint Alphonsus Regional $\mathbf{\nabla}$ Stony Brook University University of Massachusetts V Kaiser, Los Angeles Duke University V **Cleveland Clinic** Barrow Neurological Institute Medical College of Wisconsin V Georgetown University $\mathbf{\nabla}$ University of Michigan Texas Neurology V Las Vegas Clinic Beth Israel Deaconess Medical Center V George Washington University SUNY Upstate Mavo Clinic Florida V Spectrum Health V University of Kentucky Henry Ford Hospital Houston Methodist \mathbf{V} Essentia Health $\mathbf{\nabla}$ Hackensack University University of Southern California University of South Florida University of Colorado Site Map & Contacts: Providence Brain and Spine University of Minnesota Loma Linda University University of Iowa Swedish Medical Center Ohio State University

https://bit.lv/3g2NZr5

- University of Cincinnati $\mathbf{\nabla}$ Thomas Jefferson University
- V UC San Francisco
- $\mathbf{\nabla}$ Mayo Rochester

V

 $\mathbf{\nabla}$

 $\mathbf{\nabla}$

V

V

V

 $\mathbf{\nabla}$

 $\mathbf{\nabla}$

 \mathbf{V}

V

V

 \mathbf{V}

 $\mathbf{\nabla}$

 \mathbf{V}

V

V

 $\mathbf{\nabla}$

V

V

V

V

 $\mathbf{\nabla}$

 $\mathbf{\nabla}$

 \mathbf{V}

 $\mathbf{\nabla}$

 $\mathbf{\nabla}$

 $\mathbf{\nabla}$

 \mathbf{V}

V

V

 $\mathbf{\nabla}$

- V
- V Vanderbilt University
- University of Washington

Enrollment Updates (as of Dec 15, 2022)

• 185 individuals have signed informed consent

132 individuals have been randomized within Regimen E


Thank You

This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality





Regimen D

Regimen E

Regimen F

Regimen G

Regimen F

PRESS RELEASE · 5 MINUTE READ · JUL | 12 | 2022

Investigational drug ABBV-CLS-7262 initiates design phase for entry into the HEALEY ALS Platform Trial



ABBV-CLS-7262 targets eIF2B, a key regulator of the integrated stress response (ISR). In neurons exposed to cellular stressors, inhibition of the ISR by ABBV-CLS-7262 restores protein synthesis and dissolves pre-formed TDP-43 containing stress granules. This effect of ABBV-CLS-7262 is of clinical interest because TDP-43 containing stress granules are thought to lead to TDP-43 inclusions, a hallmark of ALS pathology.



Regimen G

PRESS RELEASE · DEC | 5 | 2022

Healey & AMG Center for ALS announces new drug regimen for testing DNL343 in HEALEY ALS Platform Trial

- DNL343 is being developed by Denali Therapeutics.
- It targets eIF2B, a key regulator of the integrated stress response, to restore protein synthesis and dissolve pre-formed TDP-43 containing stress granules which are thought to lead to TDP-43 inclusions, a hallmark of ALS pathology.

"By adding one more drug to the platform, we continue to push research forward in hopes of soon finding many more effective treatments for ALS."

Merit Cudkowicz, MD, MSc

Director, Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital



https://bit.ly/3uwypuU

Patient Navigation Central resource for people living with ALS



Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:

Catherine Small





https://bit.ly/3r6Nd2L

Upcoming Webinars:

December 22nd- Canceled for holidays **December 29th-** Canceled for holidays

Allison Bulat



ALS Link sign-up:



https://bit.ly/3o2Ds3m

New Expanded Access Video

Sean M. Healey & AMG Center for ALS Expanded Access Program, with TechVsALS



Watch Video:



https://bit.ly/3HCwGw3

- Direct YouTube Link: <u>https://www.youtube.com/watch?v=25-EeCwpEnU</u>
- Mass General's EAP Webpage: https://www.massgeneral.org/neurology/als/research/expanded-access